Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Placenta injection may ease shoulder pain

NCT ID NCT05528705

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an injection made from human placenta, called LAENNEC, can reduce shoulder pain in people with shoulder impingement syndrome. 50 adults with shoulder pain received either the LAENNEC injection or a placebo, guided by ultrasound. The main goal was to see if pain scores improved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Sep 2022

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At the time of screening, 19 or 70 years 2. Those who are suspected of rotator cuff lesions or damage due to shoulder pain 3. Those who are judged to have a shoulder joint disease during screening 4. Neer test, Hawkins-Kennedy inspection, job test, Painful Arc inspection or resisted showder external rotation test 5. Those with a significant pain of 30 mm of Visual Analogue Scale (VAS) 6. Those who can sign a test subject or to comply with the matters required for clinical trials. Exclusion Criteria: 1. A person who appears in the movement of two or more shoulder joints with more than 50% of the joint movement limit on the passive shoulder joint operation scope test. 2. Those who have confirmed the rupture of the entire layer by ultrasound 3. Those with serious damage to the shoulders and the past power 4. Those who have suspected fractures, dislocations, degenerative arthritis, and calcification in the shoulder radiation test in the shoulder radiation test. 5. Those who complain of shoulder pain due to stroke, spinal cord injury, and other surgery 6. Those with other shoulder diseases other than fifty dogs (rheumatoid arthritis, osteoarthritis, bone defect injuries, malignant tumors, etc.) 7. Those who are accompanied by diseases of cervical spine or other upper limbs that have a significant effect on the shoulder 8. Those who have performed steroid injections in the joint steel within 3 months of participation in clinical trials 9. Those who have administered anti -inflammatory drugs within two weeks of participation in clinical trials 10. Those with all other joint diseases that have musculoskeletal diseases that may affect effective evaluation, or that it is impossible to participate in this clinical trial. 11. Those who are diagnosed with mental illness and taking drugs 12. Pregnant women and lactation departments, fertility women who are not willing to contraceptive during the clinical trial period 13. Those who have received medication, oriental medicine, physical therapy, and injection treatment in relation to shoulder pain within the last two weeks 14 Those who are participating in other clinical trials during screening 15\. Those who determine that other testors are inadequate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Shoulder impingement syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chung-Ang University Gwangmyeong Hospital

    Gwangmyeong, South Korea

  • Chung-Ang University Hospital

    Seoul, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.